Publications by authors named "S E Mole"

The neuronal ceroid lipofuscinoses, commonly known as Batten disease, are a group of lysosomal storage disorders affecting children. There is extensive central nervous system and retinal degeneration, resulting in seizures, vision loss and a progressive cognitive and motor decline. Enzyme replacement and gene therapies are being developed, and mRNA and oligonucleotide therapies are more recently being considered.

View Article and Find Full Text PDF
Article Synopsis
  • Batten disease, particularly juvenile CLN3 disease, involves rare neurodegenerative disorders linked to a common "1-kb" deletion in the CLN3 gene, necessitating deeper research into CLN3 transcripts in healthy samples.
  • Using PacBio long-read RNA sequencing from control tissues, researchers discovered over 100 novel CLN3 transcripts and highlighted the complexity of their expression, with no single dominant form identified.
  • These findings emphasize the need to examine both typical and atypical CLN3 protein isoforms, revealing that various transcripts may impact disease mechanisms and potential treatment strategies.
View Article and Find Full Text PDF

Background: Biallelic variants in the major facilitator superfamily domain containing 8 gene (MFSD8) are associated with distinct clinical presentations that range from typical late-infantile neuronal ceroid lipofuscinosis type 7 (CLN7 disease) to isolated adult-onset retinal dystrophy. Classic late-infantile CLN7 disease is a severe, rare neurological disorder with an age of onset typically between 2 and 6 years, presenting with seizures and/or cognitive regression. Its clinical course is progressive, leading to premature death, and often includes visual loss due to severe retinal dystrophy.

View Article and Find Full Text PDF

Diversity, equity, and inclusion play pivotal roles in advancing science and innovation by fostering a rich and supportive environment that benefits both individuals and society. UK bioscience research units are still on a journey towards being inclusive, and existing research on effecting changes in diversity, equity, and inclusion has yet to make an impact at the scale needed to transform the sector, leaving many to wonder This paper considers some of the questions that arise in addressing this, discusses what we already know and what we do not, and in doing so outlines a research agenda that aims to find out what works to effect diversity, equity and inclusion in UK bioscience.

View Article and Find Full Text PDF